Zugl.: Giessen, Universiẗat, Diss., 2008.

Bei Patienten mit ST-Strecken-Elevations-Myokardinfarkt (STEMI) ist die direkte intrakoronare Bolusverabreichung des Glykoprotein-IIb/IIIa-Rezeptorantagonist Abciximab, im Gegensatz zur periphervenösen Bolusinjektion, mit einer Reduktion von Infarktgröße und mikrovaskulärer Obstruktion sowie mit einem höheren Anteil geretteten Myokards assoziiert, vermutlich ausgelöst durch eine höhere lokale Arzneimittelkonzentration und der dadurch gesteigerten Hemmung der Plättcheninhibition. Ziel der Arbeit war es herauszufinden, ob es Unterschiede gibt bezüglich der GP-IIb/IIIa Rezeptorbesetzung und der Thrombozyteninhibition im venösen Koronarblut, welches kurz nach intrakoronarer oder periphervenöser Abciximab-Bolusinjektion entnommen wurde. Dafür wurden bei 16 Patienten mit akutem STEMI vor und unmittelbar nach der Gabe eines Abciximab-Bolus sowie nach 30 Minuten Blutproben aus dem Korornarsinus entnommen. Jeweils 8 Patienten erhielten entweder den Bolus intrakoronar oder peripher venös verabreicht. Sofort nach der Bolusapplikation war die Rezeptorbesetzung im venösem Koronarblut signifikant höher bei Patienten, die einen direkten intrakoronaren Bolus erhalten hatten, im Vergleich mit Patienten mit peripherer Bolusadministration (intrakorornarer Bolus: 93.5% [IQR 92.7–95.4], intravenöser Bolus: 74.0% [IQR 17.6–94.0], p = 0.04). Das Ausmaß der Plättcheninhibition war früh nach Bolusgabe ebenso deutlich höher bei intrakoronarer anstatt intravenöser Bolusapplikation. In der späten Blutentnahme 30 Minuten nach der Bolusapplikation konnten keine signifikanten Unterschiede zwischen beiden untersuchten Gruppen, weder bezüglich der GP-IIb/IIIa Rezeptorbesetzung noch der Thrombozytenaggregationshemmung, gefunden werden. Zusammenfassend kann man sagen, dass die direkte intrakoronare Bolusapplikation akut in eine höhere lokale Inhibition der Thrombozytenfunktion und einem größeren Anteil an geblockten GP-IIb/IIIa Rezeptoren im Vergleich zur peripher venösen Bolusinjektion resultiert. Limitierend muss die geringe Fallzahl erwähnt werden. Die Ergebnisse sollten deshalb zurückhaltend interpretiert werden.

Platelet products have a short shelf life (5 to 7 days) owing in part to the deterioration of the quality of platelets stored at 22°C. This creates significant inventory challenges, and blood banks may suffer shortages and high wastage as a result. Proteomics offers a global quantitative approach to investigate changes occurring in stored blood products. These data sets can identify processes leading to storage-associated losses of blood component quality such as the platelet storage lesion (PSL). Changes to the platelet proteome between days 1 and 7 of storage were analysed with 3 complementary proteomic approaches with final mass spectrometric (MS) analysis: 2-dimensional (2D) gel electrophoresis/differential gel electrophoresis (DIGE), isobaric tagging for relative and absolute quantification (iTRAQ), and isotope-coded affinity tagging (ICAT). Although proteomics analyses identified many storage-associated protein changes, these varied significantly by method suggesting that a combination of protein-centric (2D gel or DIGE) and peptide-centric (iTRAQ or ICAT) approaches is necessary to acquire the most informative data. Validation of the proteomics results by western blotting, flow cytometry, quantitative real-time polymerase chain reaction (qRT PCR) and ³ٰ⁵S-methionine incorporation confirmed that platelets are capable of synthesising biologically relevant proteins ex vivo throughout a 10-day storage period with particularly long-lived mRNA (half-life of approximately 2.4 days), and has provided the first evidence for one of the mechanisms of the PSL. The development of an ³ٰ⁵Smethionine assay has since shown that stored human blood platelets incorporate ³ٰ⁵S-methionine at a rate that is proportional to time and substrate concentration, and is slower for freshly drawn platelets than those stored in pooled buffy coat derived units for 10 days. More interesting still are the observations that the overall ³ٰ⁵S-methionine incorporation rate was higher in pooled buffy coat platelet units versus freshly drawn platelets, that this rate increased upon agonist exposure in both, and that day 8 platelets showed significantly greater total protein translation than on days 2,3,7 and 10 of storage. This may be indicative of translational regulation of the platelet proteome during storage and upon activation. Translational control is a consequence of remarkable cellular specialisation and precise biochemical pathways which, in the case of platelets, may lead to storage-associated losses of blood component quality and must be understood if platelet storage times are to be extended.

Platelet products have a short shelf life (5 to 7 days) owing in part to the deterioration of the quality of platelets stored at 22°C. This creates significant inventory challenges, and blood banks may suffer shortages and high wastage as a result. Proteomics offers a global quantitative approach to investigate changes occurring in stored blood products. These data sets can identify processes leading to storage-associated losses of blood component quality such as the platelet storage lesion (PSL). Changes to the platelet proteome between days 1 and 7 of storage were analysed with 3 complementary proteomic approaches with final mass spectrometric (MS) analysis: 2-dimensional (2D) gel electrophoresis/differential gel electrophoresis (DIGE), isobaric tagging for relative and absolute quantification (iTRAQ), and isotope-coded affinity tagging (ICAT). Although proteomics analyses identified many storage-associated protein changes, these varied significantly by method suggesting that a combination of protein-centric (2D gel or DIGE) and peptide-centric (iTRAQ or ICAT) approaches is necessary to acquire the most informative data. Validation of the proteomics results by western blotting, flow cytometry, quantitative real-time polymerase chain reaction (qRT PCR) and ³ٰ⁵S-methionine incorporation confirmed that platelets are capable of synthesising biologically relevant proteins ex vivo throughout a 10-day storage period with particularly long-lived mRNA (half-life of approximately 2.4 days), and has provided the first evidence for one of the mechanisms of the PSL. The development of an ³ٰ⁵Smethionine assay has since shown that stored human blood platelets incorporate ³ٰ⁵S-methionine at a rate that is proportional to time and substrate concentration, and is slower for freshly drawn platelets than those stored in pooled buffy coat derived units for 10 days. More interesting still are the observations that the overall ³ٰ⁵S-methionine incorporation rate was higher in pooled buffy coat platelet units versus freshly drawn platelets, that this rate increased upon agonist exposure in both, and that day 8 platelets showed significantly greater total protein translation than on days 2,3,7 and 10 of storage. This may be indicative of translational regulation of the platelet proteome during storage and upon activation. Translational control is a consequence of remarkable cellular specialisation and precise biochemical pathways which, in the case of platelets, may lead to storage-associated losses of blood component quality and must be understood if platelet storage times are to be extended.

Platelet products have a short shelf life (5 to 7 days) owing in part to the deterioration of the quality of platelets stored at 22°C. This creates significant inventory challenges, and blood banks may suffer shortages and high wastage as a result. Proteomics offers a global quantitative approach to investigate changes occurring in stored blood products. These data sets can identify processes leading to storage-associated losses of blood component quality such as the platelet storage lesion (PSL). Changes to the platelet proteome between days 1 and 7 of storage were analysed with 3 complementary proteomic approaches with final mass spectrometric (MS) analysis: 2-dimensional (2D) gel electrophoresis/differential gel electrophoresis (DIGE), isobaric tagging for relative and absolute quantification (iTRAQ), and isotope-coded affinity tagging (ICAT). Although proteomics analyses identified many storage-associated protein changes, these varied significantly by method suggesting that a combination of protein-centric (2D gel or DIGE) and peptide-centric (iTRAQ or ICAT) approaches is necessary to acquire the most informative data. Validation of the proteomics results by western blotting, flow cytometry, quantitative real-time polymerase chain reaction (qRT PCR) and ³ٰ⁵S-methionine incorporation confirmed that platelets are capable of synthesising biologically relevant proteins ex vivo throughout a 10-day storage period with particularly long-lived mRNA (half-life of approximately 2.4 days), and has provided the first evidence for one of the mechanisms of the PSL. The development of an ³ٰ⁵Smethionine assay has since shown that stored human blood platelets incorporate ³ٰ⁵S-methionine at a rate that is proportional to time and substrate concentration, and is slower for freshly drawn platelets than those stored in pooled buffy coat derived units for 10 days. More interesting still are the observations that the overall ³ٰ⁵S-methionine incorporation rate was higher in pooled buffy coat platelet units versus freshly drawn platelets, that this rate increased upon agonist exposure in both, and that day 8 platelets showed significantly greater total protein translation than on days 2,3,7 and 10 of storage. This may be indicative of translational regulation of the platelet proteome during storage and upon activation. Translational control is a consequence of remarkable cellular specialisation and precise biochemical pathways which, in the case of platelets, may lead to storage-associated losses of blood component quality and must be understood if platelet storage times are to be extended. / Medicine, Faculty of / Biochemistry and Molecular Biology, Department of / Graduate

p83 é uma proteína com massa molecular aparente de 83 kDa, supostamente ainda não descrita, específica de sistema nervoso, e desenvolvimento regulada. p83 interage fortemente com laminina, Tau, tubulina e heat shock protein 90. p83 foi inicialmente detectada por imunohistoquímica e western blot usando-se um anticorpo anti-lectina KM+ purificado por afinidade. Sua purificação a partir de cérebro de rato está em progresso. Identificar o envolvimento de p83 em processos do Sistema Nervoso Central humano é um passo necessário em direção à compreensão de sua função biológica. Uma biblioteca de expressão de cDNA de cerebelo de rato (Lambda ZAP II, Stratagene) foi submetida ao screening, usando-se um anticorpo específico para isolar o cDNA de p83. O anticorpo anti-KM+ foi pré-adsorvido contra proteínas de E. coli XL1 Blue MRF, antes de ser usado no screening. As membranas foram reveladas por imunodetecção cromogênica (fosfatase alcalina e NBT/BCIP). A análise de todos os clones Lambda ZAP II foi feita por excisão in vivo do fagomídeo pBluescript, subclonagem em E. coli XL1 Blue MRF, purificação do DNA plasmidial e digestão com Eco RI. A seqüência correspondente ao clone isolado foi analisada usando-se ferramentas e bancos de dados do NCBI. A seqüência nucleotídica mostrou identidade com as isoformas A e E de drebrina. As isoformas A e E de drebrina foram detectadas em adulto e embrião, respectivamente. Drebrina A é uma proteína sistema nervoso-específica, desenvolvimento regulada e associa-se com F-actina. Embora drebrina e p83 compartilhem propriedades em comum, nossos dados de western blot indicaram que parecem não se tratar da mesma proteína. Nós investigamos a expressão de drebrina em Displasia Cortical Focal tipo IIB, comparando com córtex normal. As secções de tecido foram coradas com hematoxilina-eosina e prata (Bielchowsky). Secções foram processadas por imunohistoquímica usando-se os anticorpos anti-drebrina M2F6 e o DAS2, e recuperação antigênica. A detecção foi feita usando-se um anticorpo biotinilado, e DAB como cromógeno. Os tecidos displásicos (13 casos) foram obtidos cirurgicamente de tecidos exibindo epilepsia droga-resistente. Os controles foram obtidos de necrópsia de 15 pacientes sem história prévia de doenças neurológicas ou alterações patológicas. Nossos resultados sugerem uma associação entre drebrina e DCF IIB, um distúrbio do desenvolvimento cortical. / p83 is 83 kDa protein supposedly not yet described, nervous system specific, and developmentally regulated. p83 strongly interacts with laminin, Tau, tubulin and heat shock protein 90. It was initially detected by immunohistochemistry and western blot using an affinity-purified anti-lectin KM+ antibody. Its purification from rat brain is in progress. Identifying the involvement of p83 in human Central Nervous System processes is a required step towards understanding its biological roles. A premade cDNA rat cerebellum expression library (Lambda ZAP II, Stratagene) has been screened, using a specific antibody to isolate p83 cDNA. Anti-KM+ antibody was pre-adsorbed against E. coli XL1 Blue MRF proteins, before using in screening. Membranes were revealed by cromogenic immunodetection (alcaline fostase and NBT/BCIP). The analysis of all positive Lambda ZAP II clones was carried out by in vivo excision of pBluescript, subcloning in E. coli XL1 Blue MRF, plasmidial DNA purification and Eco RI digestion. The sequence corresponding to the clone isolated was analyzed using the NCBI tools and database. The nucleotide sequence showed identity with drebrin A and E isoforms. Drebrin A and E isoforms were detected in adults and embryos. Drebrin A is a neuron-specific, development-regulated F-actin-binding protein. It participates in growth cone extension and dendritic spine formation. Although have same drebrin and p83 properties in common, they not seem to be the same protein. We have investigated the expression of drebrin in Focal Cortical Dysplasia type IIB (FCD IIB) as compared to normal cortex. Tissue sections were stained with hematoxylin-eosin and silver (Bielchowsky). Sections were processed for immunohistochemistry using anti-drebrin antibodies M2F6 and DAS2, and an antigen retrieval technique. Detection was carried out using a biotinylated antibody, using DAB as chromogen. Dysplastic tissues (13 cases) were obtained at surgery for drug-resistant epilepsy. Controls were obtained at autopsy from 15 patients without history of neurological disorder and gross pathological changes. A specific drebrin labeling in dysplastic tissue was more intense than in controls. Indeed, most control cases exhibited at most a slightly higher staining than the background. Balloon, clear and undetermined cells, and giant, dysmorphic neurons, showed a conspicuous labeling by anti-drebrin. These cells showed a thin rim labeling of the nuclear membrane, and a finely punctate nuclear labeling. In contrast, a coarse nuclear, but a faint cytoplasm labeling was observed in autopsy cases. Our data suggest an association between Drebrin expression and the FCD IIB, a disturbance of cortical development.

p83 é uma proteína com massa molecular aparente de 83 kDa, supostamente ainda não descrita, específica de sistema nervoso, e desenvolvimento regulada. p83 interage fortemente com laminina, Tau, tubulina e heat shock protein 90. p83 foi inicialmente detectada por imunohistoquímica e western blot usando-se um anticorpo anti-lectina KM+ purificado por afinidade. Sua purificação a partir de cérebro de rato está em progresso. Identificar o envolvimento de p83 em processos do Sistema Nervoso Central humano é um passo necessário em direção à compreensão de sua função biológica. Uma biblioteca de expressão de cDNA de cerebelo de rato (Lambda ZAP II, Stratagene) foi submetida ao screening, usando-se um anticorpo específico para isolar o cDNA de p83. O anticorpo anti-KM+ foi pré-adsorvido contra proteínas de E. coli XL1 Blue MRF, antes de ser usado no screening. As membranas foram reveladas por imunodetecção cromogênica (fosfatase alcalina e NBT/BCIP). A análise de todos os clones Lambda ZAP II foi feita por excisão in vivo do fagomídeo pBluescript, subclonagem em E. coli XL1 Blue MRF, purificação do DNA plasmidial e digestão com Eco RI. A seqüência correspondente ao clone isolado foi analisada usando-se ferramentas e bancos de dados do NCBI. A seqüência nucleotídica mostrou identidade com as isoformas A e E de drebrina. As isoformas A e E de drebrina foram detectadas em adulto e embrião, respectivamente. Drebrina A é uma proteína sistema nervoso-específica, desenvolvimento regulada e associa-se com F-actina. Embora drebrina e p83 compartilhem propriedades em comum, nossos dados de western blot indicaram que parecem não se tratar da mesma proteína. Nós investigamos a expressão de drebrina em Displasia Cortical Focal tipo IIB, comparando com córtex normal. As secções de tecido foram coradas com hematoxilina-eosina e prata (Bielchowsky). Secções foram processadas por imunohistoquímica usando-se os anticorpos anti-drebrina M2F6 e o DAS2, e recuperação antigênica. A detecção foi feita usando-se um anticorpo biotinilado, e DAB como cromógeno. Os tecidos displásicos (13 casos) foram obtidos cirurgicamente de tecidos exibindo epilepsia droga-resistente. Os controles foram obtidos de necrópsia de 15 pacientes sem história prévia de doenças neurológicas ou alterações patológicas. Nossos resultados sugerem uma associação entre drebrina e DCF IIB, um distúrbio do desenvolvimento cortical. / p83 is 83 kDa protein supposedly not yet described, nervous system specific, and developmentally regulated. p83 strongly interacts with laminin, Tau, tubulin and heat shock protein 90. It was initially detected by immunohistochemistry and western blot using an affinity-purified anti-lectin KM+ antibody. Its purification from rat brain is in progress. Identifying the involvement of p83 in human Central Nervous System processes is a required step towards understanding its biological roles. A premade cDNA rat cerebellum expression library (Lambda ZAP II, Stratagene) has been screened, using a specific antibody to isolate p83 cDNA. Anti-KM+ antibody was pre-adsorbed against E. coli XL1 Blue MRF proteins, before using in screening. Membranes were revealed by cromogenic immunodetection (alcaline fostase and NBT/BCIP). The analysis of all positive Lambda ZAP II clones was carried out by in vivo excision of pBluescript, subcloning in E. coli XL1 Blue MRF, plasmidial DNA purification and Eco RI digestion. The sequence corresponding to the clone isolated was analyzed using the NCBI tools and database. The nucleotide sequence showed identity with drebrin A and E isoforms. Drebrin A and E isoforms were detected in adults and embryos. Drebrin A is a neuron-specific, development-regulated F-actin-binding protein. It participates in growth cone extension and dendritic spine formation. Although have same drebrin and p83 properties in common, they not seem to be the same protein. We have investigated the expression of drebrin in Focal Cortical Dysplasia type IIB (FCD IIB) as compared to normal cortex. Tissue sections were stained with hematoxylin-eosin and silver (Bielchowsky). Sections were processed for immunohistochemistry using anti-drebrin antibodies M2F6 and DAS2, and an antigen retrieval technique. Detection was carried out using a biotinylated antibody, using DAB as chromogen. Dysplastic tissues (13 cases) were obtained at surgery for drug-resistant epilepsy. Controls were obtained at autopsy from 15 patients without history of neurological disorder and gross pathological changes. A specific drebrin labeling in dysplastic tissue was more intense than in controls. Indeed, most control cases exhibited at most a slightly higher staining than the background. Balloon, clear and undetermined cells, and giant, dysmorphic neurons, showed a conspicuous labeling by anti-drebrin. These cells showed a thin rim labeling of the nuclear membrane, and a finely punctate nuclear labeling. In contrast, a coarse nuclear, but a faint cytoplasm labeling was observed in autopsy cases. Our data suggest an association between Drebrin expression and the FCD IIB, a disturbance of cortical development.

Bei Patienten mit ST-Strecken-Elevations-Myokardinfarkt (STEMI) ist die direkte intrakoronare Bolusverabreichung des Glykoprotein-IIb/IIIa-Rezeptorantagonist Abciximab, im Gegensatz zur periphervenösen Bolusinjektion, mit einer Reduktion von Infarktgröße und mikrovaskulärer Obstruktion sowie mit einem höheren Anteil geretteten Myokards assoziiert, vermutlich ausgelöst durch eine höhere lokale Arzneimittelkonzentration und der dadurch gesteigerten Hemmung der Plättcheninhibition. Ziel der Arbeit war es herauszufinden, ob es Unterschiede gibt bezüglich der GP-IIb/IIIa Rezeptorbesetzung und der Thrombozyteninhibition im venösen Koronarblut, welches kurz nach intrakoronarer oder periphervenöser Abciximab-Bolusinjektion entnommen wurde. Dafür wurden bei 16 Patienten mit akutem STEMI vor und unmittelbar nach der Gabe eines Abciximab-Bolus sowie nach 30 Minuten Blutproben aus dem Korornarsinus entnommen. Jeweils 8 Patienten erhielten entweder den Bolus intrakoronar oder peripher venös verabreicht. Sofort nach der Bolusapplikation war die Rezeptorbesetzung im venösem Koronarblut signifikant höher bei Patienten, die einen direkten intrakoronaren Bolus erhalten hatten, im Vergleich mit Patienten mit peripherer Bolusadministration (intrakorornarer Bolus: 93.5% [IQR 92.7–95.4], intravenöser Bolus: 74.0% [IQR 17.6–94.0], p = 0.04). Das Ausmaß der Plättcheninhibition war früh nach Bolusgabe ebenso deutlich höher bei intrakoronarer anstatt intravenöser Bolusapplikation. In der späten Blutentnahme 30 Minuten nach der Bolusapplikation konnten keine signifikanten Unterschiede zwischen beiden untersuchten Gruppen, weder bezüglich der GP-IIb/IIIa Rezeptorbesetzung noch der Thrombozytenaggregationshemmung, gefunden werden. Zusammenfassend kann man sagen, dass die direkte intrakoronare Bolusapplikation akut in eine höhere lokale Inhibition der Thrombozytenfunktion und einem größeren Anteil an geblockten GP-IIb/IIIa Rezeptoren im Vergleich zur peripher venösen Bolusinjektion resultiert. Limitierend muss die geringe Fallzahl erwähnt werden. Die Ergebnisse sollten deshalb zurückhaltend interpretiert werden.

B cells are normally regulated to prevent activation against self-proteins through tolerance mechanisms.  However, occasionally there is a break in tolerance and B cells can become self-reactive, which might lead to the development of autoimmune disease. The activation of self-reactive B cells is regulated by receptors on the B cell surface, such as Fc gamma receptor IIb (FcγRIIb), complement receptor type 1 (CR1), and CR type 2 (CR2). In this thesis I have studied the role of FcγRIIb, CR1 and CR2 on B cells in autoimmune arthritis. By using a model for rheumatoid arthritis, I discovered that the initial self-reactive B cell response in arthritis was associated with the splenic marginal zone B cell population. Marginal zone B cells express high levels of CR1/CR2 and FcγRIIb, suggesting that they normally require high regulation. Further, female mice deficient in CR1/CR2 displayed increased susceptibility to arthritis compared to CR1/CR2-sufficient female mice. When investigating whether sex hormones affected arthritis susceptibility, we found that ovariectomy, of the otherwise fairly resistant CR1/CR2-sufficient mice, reduced the expression of CR1 on B cells and rendered the mice more susceptible to arthritis. In humans, a significantly reduced CR1 and FcγRIIb expression was found on B cells in aging women, but not in men. This may contribute to the increased risk for women to develop autoimmune disease as reduced receptor expression may lead to the activation of self-reactive B cells. In agreement, lower CR1, CR2 and FcγRIIb expression was seen in patients with rheumatoid arthritis.   Finally, a soluble form of FcγRIIb was used to investigate FcγRIIb’s ability to bind self-reactive IgG in an attempt to treat autoimmune arthritis. Treatment of mice with established arthritis was associated with less self-reactive IgG antibodies and consequently less disease, suggesting that soluble FcγRIIb may be used as a novel treatment in arthritis.

Cattle are vitally important to American agriculture industry, generating over 24.6 billion pounds of beef (by carcass weight), and 79.5 billion dollars in 2005, and over 27 billion dollars in milk sales in 2004. As of July 2006, the U.S. beef and dairy industry is comprised of 104.5 million head of cattle, 32.4 million of which were processed in 2005. The health of the animals has always been an important concern for breeders, as healthy animals grow faster and are more likely to reach market weight. Animals that exhibit natural resistance to disease do not require chemicals to stimulate normal weight gain, and are less prone to disease related wasting. The major histocompatibility complex (MHC) is a collection of genes, many of which function in antigen processing and presentation. The bovine MHC (BoLA) differs from typical mammalian MHCs in that the class II region was disrupted by a chromosomal inversion into two subregions, designated BoLA IIa and BoLA IIb. BoLA IIb was transposed to a position near the centromere on bovine chromosome 23,while BoLA IIa retains its position in BoLA. Comparative sequence analysis of BoLA IIb with the human MHC revealed the location of the region containing the proximal inversion breakpoint. Gene content, order and orientation of BoLA IIb are consistent with the single inversion hypothesis when compared to the corresponding region of the human class II MHC (HLA class II). BoLA IIb spans approximately 450 kb. The genomic sequence of BoLA IIb was used to detect sequence variation through comparison to other bovine sequences, including data from the bovine genome project, and two regions in the BAC scaffold used to develop the BoLA IIb sequence. Analysis of the bovine genome project sequence revealed a total of 10,408 mismatching bases, 30 out of 231 polymorphic microsatellites, and 15 sequences corresponding to the validated SNP panel generated by the bovine genome sequencing project. The two overlapping regions in the BoLA IIb BAC scaffold were found to have 888 polymorphisms, including a total of 6 out of 42 polymorphic microsatellites indicating that each BAC derived from a different chromosome.